Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy

Ann Hematol. 2015 Apr;94(4):687-9. doi: 10.1007/s00277-014-2214-x. Epub 2014 Sep 12.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Administration, Intravenous
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / administration & dosage*
  • Boronic Acids / administration & dosage*
  • Bortezomib
  • Dexamethasone / administration & dosage
  • Disease Progression
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Injections, Subcutaneous
  • Male
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology
  • Pyrazines / administration & dosage*

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Pyrazines
  • Bortezomib
  • Dexamethasone